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Abstract
Delivery of drugs to the posterior segment of the eye is a signiﬁcant challenge in the
ﬁeld of opthalmic pharmaceuticals. Several restrictive barriers hinder drug delivery to
this district. Static barriers include tissues and limiting membranes, while dynamic
barriers include drug clearance mechanism from blood and lymphatics. Strategies for
delivering drugs to the posterior segment most often consist in topical ocular
medications or systemic administrations, but dose/response proﬁles are generally
very poor. Intravitreal injections and transscleral delivery are new emerging
techniques with promising results. Purpose of this study is to develop a mathematical
model to assess drug levels subsequent to a transscleral drug implant. Both
computational and analytical techniques are adopted. The model comprises sclera,
choroid, retina and vitreous along with the retina pigment epithelium at the
choroid-retina boundary and the inner blood retinal barrier of the retinal vessels.
Darcy equations are used to compute the ﬁltration velocity of the interstitial ﬂuid and
a ﬁctitious velocity ﬁeld is added to model active pumping from the retinal
pigmented epithelium. Convective-diﬀusive-reactive equations for drug
concentration are then solved. Permeability parameters and partition coeﬃcients
simulate the presence of internal membranes and barriers, with possible diﬀerent
values in outward and inward directions. An important result of the model is the
evaluation of the roles of the diﬀerent physical parameters, which oﬀers key points to
improve drug delivery techniques. Namely, the sensitivity study suggests that
diﬀusion in tissue, clearance rates, membrane permeabilities and active pumping play
important roles in determining drug peak concentration and time-to-peak. However,
their relative inﬂuence can be dramatically diﬀerent depending on the rate-limiting
parameter.
Keywords: ocular drug delivery; RPE active pumping; blood retinal barrier; ocular
membrane permeability; mathematical model
1 Introduction
The understanding of drug delivery mechanisms in the posterior segment of the eye (PSE)
- including sclera, choroid and retina - is one of the most challenging tasks in the phar-
maceutical industry []. The eﬃciency of drug delivery to the PSE is hindered by several
barriers. Static barriers consist of physical obstacles to drug diﬀusion such as the sclera
itself, the retinal pigment epithelium (RPE, the so-called outer blood retinal, oBRB) and
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the retinal vessels (the so-called inner blood retinal barrier, iBRB). Dynamic barriers in-
clude drug clearance mechanisms through blood and lymphatic vessels and degradation
processes. Drug solubility, lipophilicity, charge, degree of ionization, molecular size and
shape aﬀect the penetration rate of the drug across the various barriers []. Convection by
interstitial ﬂuid ﬁltration can play a certain role especially when considering low-diﬀusible
molecules []. There is also considerable evidence suggesting that active transport (‘pump-
ing’) across the RPE can induce signiﬁcant eﬀects, sucking out ﬂuid, and thus dissolved
drugs, from the retina towards the choroid [, ].
Literature on mathematical models of the pharmacokinetics of ocular and periocular
delivery systems is relatively sparse (see Chapter  of [] for a recent review on this sub-
ject). Table  presents - at the best of our knowledge - a schematic survey of the existing
most recent mathematical models of ocular drug delivery. There is a general agreement in
distinguishing between small (molecular weight <  kDa, as ﬂuoroscein) and large (molec-
ular weight >  kDa, as albumin, antibodies) molecules, since they display diﬀerent dif-
fusivities. Interstitial ﬂuid ﬁltration is also kept into account in several papers by Darcy
equations, under the hypothesis of steady ﬂow. Interface boundary conditions for the drug
concentration between diﬀerent subdomains (vitreous, retina, choroid, sclera or combi-
Table 1 Schematic prospect of existing mathematical models in recent literature on ocular
drug delivery
Symbols: nD, n = 0, 1, 3: spatial dimensions of the model; V = vitreous, R = retina, C = choroid, S = sclera. a : treated with an
addictional ﬁctitious advective term; b : treated with different inward and outward membrane permeabilities. Merged cells in
a row indicate that the corresponding domains are treated as a sole entity. Interface boundary conditions are checked when
a Robin-type boundary conditions with a speciﬁc membrane permeability is used for drug at interface; c : a partition
coefﬁcient is considered at the interface; d : Navier-Stokes equations are considered.
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nations of them) are assigned via simple continuity of normal ﬂuxes or via more complex
Robin-type conditionsmodeling the presence of a permeablemembrane.More controver-
sial, less investigated, points are represented by the inclusion of active transport mecha-
nisms (see [, ]) and the interaction of the drug with blood ﬂow in circulatory vessels (see
[, ]). These latter aspects turn out to be very relevant when computing drug levels in the
retina after periocular administration. The retina is an important therapeutic target but
only a few studies address it speciﬁcally (refer to Table ). The present paper aims at ad-
dressing this topic. We present a D model including vitreous, retina, choroid and sclera
subdomains with a blood phase in the retina. We compute the ﬁltration velocity of the
interstitial ﬂuid and we solve convective-diﬀusive-reactive equations for drug concentra-
tion. Permeability parameters and partition coeﬃcients simulate the presence of internal
membranes and barriers. We carry out numerical simulations based on transscleral drug
delivery, which is an attractive alternative to the intravitreous mode of administration.
We investigate the problem sensitivity with respect to the above mentioned parameters,
which allow to evaluate the importance of tuning these properties when devising a new
drug and their relative importance.
The paper is organized as follows. In Section , we present the geometrical assumptions
and the mathematical model of the PSE. In Section , we show the results obtained from
numerical solution of the mathematical model and sensitivity analysis. In Section , we
discuss the signiﬁcance of the model and the main results relevant for devising new drug
formulations and delivery techniques. Eventually, in Section , we draw the conclusions of
thework. A theoretical analysis is carried out in theAppendix to establish lower and upper
bounds for the drug concentration in the retina, an important target for drug delivery.
2 Mathematical model of the posterior segment of the eye
2.1 Geometrical description of the PSE
Compartmental models of the PSE have been presented in [–] to describe drug ad-
ministration via a subconjunctival application or an episcleral hydrogel implant. Consen-
sus has been reached about the necessity of including separate compartments which rep-
resent the diﬀerent anatomical structures in the PSE. In [], a study has been carried out
to evaluate the compartment subdivision which provides the best ﬁtting of experimen-
tal data. The most eﬀective identiﬁed conﬁguration includes compartments representing
site of drug release, periocular tissue, sclera/choroid/RPE, retina and a non-speciﬁed dis-
tribution compartment. An analogous identiﬁcation of relevant independent structures
is carried out in [], where a D continuum model describes levels of ﬂuoroscein after
periocular administration.
According to the above arguments, we model the PSE as the union of four diﬀerent
layers, treated as D slabs (see Figure ), representing:
• sclera (S), an avascular and largely acellular coat of extracellular matrix relatively
permeable to molecules;
• choroid (C), a dense network of large and small blood vessels with a relatively sparse
population of cells;
• retina (R), composition of several layers of densely packed neuronal and glial cells,
vascularized by arterioles and venules which run superﬁcially along the retinal inner
surface and supply/drain the embedded capillary plexi (see Figure , top panel);
• vitreous (V), a clear, avascular, gelatinous body which accounts for about % of the
volume of the eye.
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Figure 1 Globe of the eye and schematics of the PSE regions considered in the mathematical model.
RPE: retinal pigmented epithelium, oBRB: outer blood retinal barrier, iBRB: internal blood retinal barrier, ILM:
internal limiting membrane.
Figure 2 Schematic depiction of retinal
circulation and corresponding mathematical
model. Top: retinal tissue and circulation. Blood
vessels are embedded in the inner retinal region,
while the outer retina is avascular. The rightmost
plexum is the arteriolar/venular network, middle and
leftmost plexi are constitued by capillary networks.
In the retinal tissue, diﬀerent types of neural cells are
represented. Bottom: mathematical representation
of the function φ , volumetric fraction of blood in the
multiphase model. The maximal values are attained
in correspondance of the vessel plexi.
We denote by S = (,LSC), C = (LSC ,LCR), R = (LCR,LRV ) and V = (LRV ,LV ) the
computational domains corresponding to the S, C, R, V layers, respectively. For j =
S,C,R,V , we denote by nj its unit normal vector directed outward. For i = S,C,R and
j = C,R,V , we denote by ij the interface between two adjacent layers i and j.
2.2 Mathematical model of the PSE
Let j = S,C,R,V . For space x ∈ j and time t ∈ (,T), we let vj = vj(x) (cm/s) be the steady
ﬁltration (seepage) velocity in layer j, (K/μ)j the corresponding hydraulic conductivity
(cm/mmHg/s). We let Cj = Cj(t,x) (g/cm) be the drug concentration in layer j and Dj
(cm/s) and kj (/s) the corresponding drug diﬀusivity and clearance/decay rate, respec-
tively. For i = S,C,R and j = C,R,V , we let Rij (cm/s/mmHg) be the membrane hydraulic
permeability at the interface ij and we let Lij (cm/s) and Pij (·) be the drug membrane
permeability and the partition coeﬃcient between the two layers.
Filtration velocity in the PSE. We model the interstitial ﬂow as an incompressible ﬂuid
which permeates through the PSE porous layers according to the steady-state Darcy equa-
tion:
vj = –
(K
μ
)
j
∂pj
∂x , ()
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pj = pj(x) being the hydrostatic pressure. For i = S,C,R and j = C,R,V , the following con-
ditions hold at the interface ij:
• velocity continuity
vi · ni = vj · ni;
• pressure jump condition (reduced Kedem-Katchalsky conditions for solvent, see
e.g., [])
vi · ni =Rij(pi – pj).
Drug mass balance in the PSE. Drug mass balance is enforced in each layer according to
the characteristic features of the layer itself.
In the sclera and vitreous, the following equation holds:
∂Cj
∂t =Dj
∂Cj
∂x – vj
∂Cj
∂x – kjCj, j = S,V , ()
where vj is computed from equation () in layer j.
Drugs in the choroid bloodstream rapidly equilibrate with the extravascular space, due
to the fenestrated structure of choriocapillaris [, ]. For this reason, a unique concen-
tration value is considered both for tissue and blood domains, yielding
∂CC
∂t = SC(t) +DC
∂CC
∂x – vC
∂CC
∂x – kCCC , ()
where SC = SC(t) is a systemic drug source rate, vC is computed from equation () solved
in the choroid and kC the clearance rate due to choriocapillaries.
Drug concentration in the retina is modeled assuming the domain to contain a mixture
of tissue and blood vessels. We denote by φ = φ(x) ∈ (, ) the retinal vascular porosity,
which represents the volumetric fraction occupied by the vascular space, the remaining
volumetric fraction being extravascular space. We have that φ →  in the inner regions
where the vascular beds are located and φ →  in the outer regions. We consider a math-
ematical representation of the function φ as in Figure  (bottom panel) which results from
the superposition of Gaussian functions centered in the anatomical location of each vessel
plexum. The standard deviation of the Gaussian is chosen in such a way that the function
is signiﬁcantly greater than zero in a region roughly corresponding to the thickness of
the vessel plexum itself (superﬁcial layer and two capillary beds). We let β = β(φ) (/s)
be the rate of drug transport across the blood vessels representing the eﬀect of the iBRB
(see also [, ]). We set β = LvwAvesselρ , where Lvw  – (cm/s) is the permeability of
the blood vessel wall [], Avessel   · – (cm) the average lateral surface of a vessel
(arteriole, capillary, venule []) and ρ = ρmaxφ the number of vessels per cm of tissue,
with ρmax  . ·  (/cm) []. Denoting by CRt = CRt(t,x) and CRb = CRb(t,x) the
drug concentration in tissue and vascular spaces, respectively, drug mass conservation is
represented by the system:
⎧⎪⎨
⎪⎩
( – φ)∂CRt
∂t = ( – φ)[DR
∂CRt
∂x – (vRt + vact)
∂CRt
∂x – kRtCRt] + β(CRb –CRt),
φ
dCRb
dt = SRb(t,x) – β(CRb –CRt) – φkRbCRb,
()
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where SRb(t,x) = φ(x)λ(t) is a prescribed rate of drug concentration from systemic sources
and vRt is computed from equation () solved in the retina. The additional ﬁltration ve-
locity vact , pointing towards the negative x direction, is included in equation () to model
active pumping by the RPE, which extracts ﬂuid from the retina towards the choroid [].
For i = S,C,R and j = C,R,V , the following conditions for drug concentration are en-
forced at the interface ij:
• drug ﬂux continuity
Di
∂Ci
∂x · ni =Dj
∂Cj
∂x · ni;
• drug concentration jump condition (reduced Kedem-Katchalsky conditions for solute,
see e.g., [])
–Di
∂Ci
∂x · ni =Lij(PijCi –Cj),
where the partition coeﬃcient Pij takes into account the possible diﬀerent
hydrophilicity/lipophilicity between layers i and j.
The complete model for amounts to solve equation () along with equations ()-() with
the respective interface conditions. We enforce at the external boundary of the vitreous a
hydrostatic pressure equal to  mmHg, corresponding to a normal intraocular pressure
(IOP), and at the external boundary of the sclera a hydrostatic pressure equal to mmHg,
corresponding to the episcleral venous pressure []. For the drug, if not diﬀerently speci-
ﬁed, we prescribe at the sclera external boundary a concentration exponentially decreasing
in time from the initial value  mg/cm ﬁtting the trend obtained from a model of drug
Figure 3 Drug peak concentration as a function of time in the different layers considered in the
model. The curves relative to the retina are speciﬁed into tissue and blood phases and further divided into
inner and outer region, the ﬁrst indicating the portion of the retina embedding blood vessels (function φ > 1)
and the second one the avascular portion. The inset shows a zoom for short times.
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release in posterior eye gel implants [] (black curve in Figure  of the present paper). The
vitreous is assumed to be thick enough so that there is no normal diﬀusive and convective
ﬂux of drug across its external boundary when considering episcleral drug delivery. The
drug concentration problem is supplied by the initial conditions Cj(t = ,x) = Cj,(x) = ,
j = S,C,R,V (exogenous drug).
3 Numerical simulations
The ﬂuid ﬁltration equations are solved numerically by means of the function bvp4c of
MATLAB. The drug concentration equations are solved using for time integration an ex-
plicit Runge-Kutta scheme with adaptive time step implemented by the function ode23t
of MATLAB. Spatial discretization is performed by an in-house developed code imple-
menting D linear ﬁnite elements with stabilization techniques for possibly advection-
dominated problems. The parameters used in the simulations are reported in Table .
Notice that the external source terms SC and SRb may be non-zero due to (a minimal) sys-
temic drug absorption into circulation and successive release into the tissues. Being unable
to quantify such sources, it is reasonable in ﬁrst approximation to set SC = SR = .
3.1 Convective ﬁeld
Solving the Darcy equations yields a constant ﬁltration velocity of about – (cm/s). This
value is in accordance with the results of [, ]. The corresponding Péclet number based
on the layer thickness is deﬁnitely less than  when considering small weight molecules
(diﬀusivity of the order of – to – (cm/s)) and of the order  when considering large
Table 2 Value of the model parameters used in the numerical simulations (if not speciﬁed
otherwise)
Parameter Value Unit Description Ref.
tS 600 μm Sclera thickness [13]
tC 300 μm Choroid thickness [13]
tR 246 μm Retina thickness [13]
tV 15000 μm Vitreous thickness [20]
(K/μ)S 8.4 · 10–7 cm2/s Hydraulic conductivity in sclera [8]
(K/μ)C 2.35 · 10–11 cm2/s Hydraulic conductivity in choroid [8]
(K/μ)R 1.5 · 10–11 cm2/s Hydraulic conductivity in retina [8]
(K/μ)V 1.5–11 cm2/s Hydraulic conductivity in vitreous [8]
RSC 10–7 cm/s/mmHg Hydraulic permeability at SC [7, 32]
RCR 10–7 cm/s/mmHg Hydraulic permeability at CR [7, 32]
RRV 10–7 cm/s/mmHg Hydraulic permeability at RV [32]
DS 4 · 10–7 cm2/s Drug diﬀusivity coeﬃcient in sclera [13]
DC 1.6 · 10–7 cm2/s Drug diﬀusivity coeﬃcient in choroid [13]
DR 1.17 · 10–7 cm2/s Drug diﬀusivity coeﬃcient in retina [13]
DV 6 10–6 cm2/s Drug diﬀusivity coeﬃcient in vitreous [6]
kS 3 · 10–4 1/s Drug clearance/Decay coeﬃcient in sclera [13]
kC 3 · 10–4 1/s Drug clearance/Decay coeﬃcient in choroid [13]
kRt 3 · 10–4 1/s Drug clearance/Decay coeﬃcient in retinal tissue [13]
kRb 3 · 10–4 1/s Drug clearance/Decay coeﬃcient in retinal blood [13]
kV 8 · 10–5 1/s Drug clearance/Decay coeﬃcient in vitreous [11]
LSC 10–4 cm/s Permeability coeﬃcient at SC [21]
LCR 10–5 cm/s Permeability coeﬃcient at CR [11, 16]
LRV 10–5 cm/s Permeability coeﬃcient at RV [11, 16, 21]
PCS 1 adim Partition coeﬃcient at sclera/Choroid interface [21]
PCR 1/1.33 adim Partition coeﬃcient at choroid/Retina interface [13]
PRV 1/10 adim Partition coeﬃcient at retina/Vitreous interface [21]
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weight molecules (diﬀusivity of the order of – (cm/s)). When considering in the retina
the active pumping velocity, which is of the order of  ·– (cm/s) [], the ﬁltration velocity
turns out to be negligible. The Péclet number of the retina computed with the pumping
velocity rises to a value of the order of  for small molecules and  for large molecules,
so that convection is dominating.
3.2 Validation of drug concentration levels
To validate the model, we check that we reproduce comparable results in drug peak con-
centration and time-to-peak as in existing literature models. In Figure , we show drug
peak concentration as a function of time in the diﬀerent layers considered in the model.
The curves relative to the retina are speciﬁed into tissue and blood phases and further di-
vided into inner and outer region, the ﬁrst indicating the portion of the retina embedding
blood vessels (function φ > ) and the second one the avascular portion In Figures  and ,
we report results from simulations in diﬀerent literature models for molecules compara-
ble to ﬂuoroscein and for similar drug inlet boundary conditions with episcleral plug or
injection. The peak concentration value found in our simulations is comparable to the one
of the models of [] and [] (scaled inlet concentration) in the retina and to the ones of
the models of [] and [] (scaled inlet concentration) in the choroid. Time-to peak values
Figure 4 Drug peak concentration values for the
present model and literature models (data
represented are where available and upon
conversion of units of measure). Comparable
values of parameters and inlet conditions are used.
Values denoted by the symbol ‘∗’ have been
obtained by multiplying the values by 100 to scale
drug concentration at the boundary (assuming a
linear behavior as suggested by the results of [21]).
Values from [8] have been interpreted as percentage
of the enforced boundary concentration, in lack of
indications. Notice that log scale is used for the y
axis.
Figure 5 Drug time-to-peak values for the
present model and literature models (data are
represented where available and upon
conversion of units of measure). Comparable
values of parameters and inlet conditions are used.
Notice that log scale is used for the y axis.
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of our model, of the order of - (h), comparable to the results of []. Such a scattering
of the results may be ascribed to (i) diﬀerent dimensionality of the models; (ii) diﬀerent
values of the parameters (see the below sensitivity study); (iii) diﬀerent biophysical mecha-
nisms included (active pumping, ﬁltration velocity, membrane permeabilities, membrane
partition coeﬃcient). The following sensitivity analysis is aimed at clarifying the role of
the diﬀerent parameters and mechanisms.
3.3 Sensitivity study
We use now the model to study the sensitivity of the drug peak concentration and drug
time-to-peak with respect to: (i) diﬀusion coeﬃcients; (ii) clearance rates; (iii) membrane
permeabilities; (iv) convective velocity. Values of the parameters reported in Table  are
considered as the baseline condition. The ﬁltration velocity is artiﬁcially varied as a syn-
thetic index of the variation of hydraulic permeability and pressure drop and the bound-
aries. We vary each parameter individually and we plot for the retina and choroid the
resulting peak concentration (Figure ) and time-to-peak (Figure ) as a function of the
parameter value. The diﬀerent colored lines represent peak concentration or time-to-peak
when the parameter in object is changed in a certain layer (refer to the legend in each
panel). Vertical dotted lines in each panel show the parameter baseline value.
In Figure , we show the drug peak concentration as a function of time with active or
inactive selected components of the convective ﬁeld in baseline conditions. In Figure  we
show the sensitivity of the drug peak concentration and time-to-peak values in tissue and
blood phases of the retina. with respect to the diﬀerent components of the convective ﬁeld
(ﬁltration velocity and active pumping). The choroid (data not reported) results to be very
weakly sensitive to the variations in the convective ﬁeld values.
4 Discussion and conclusions
Drug delivery to the PSE is still an open issue in ocular diseases therapy. Many drugs have
a narrow concentration window within which they are eﬀective and non-toxic. Currently,
about % of the treatments of ophthalmic diseases are performed by medications ad-
ministered topically. However, drugs enter the eye through this pathway at a very limited
extent: wash oﬀ by various mechanisms (lacrimation, blinking, tear turnover) and low
permeability of the corneal epithelial membrane causes less than % of the administered
drug to eﬀectively reach the posterior targets []. Among the other possible drug deliv-
ery routes, systemic administration has a poor dose/response proﬁle in the eye. Intrav-
itreous delivery, whilst eﬃcient, can carry signiﬁcant local complications such as retinal
detachment, endophthalmitis, vitreous hemorrhage and cataract formation []. Under
these premises, sustained drug delivery to the PSE via the alternative transscleral route is
gaining increasing importance, due to the easily accessible area, the hypocellularity and
permeability of the sclera to relatively large molecules, and, importantly, to the degree of
acceptance of patients [, ]. Pharmacokinetics of drugs in the PSE following transscle-
ral delivery is an emerging issue []. The reported data are very sparse and, for the most
part, refer only to the vitreous, which is easily accessible in experiments, to draw compar-
isons.
Transscleral drug delivery has been analyzed in this paper using a D continuummodel
including diﬀusive, convective and reactive mechanisms and comprehending the sclera,
choroid, retina and vitreous domains. The presence of internal membranes has been kept
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Figure 6 Drug peak concentration in the choroid (left column) and retina (right column) as a function
of diffusion coefﬁcient (top row), clearance rate (middle row) andmembrane permeability (bottom
row) in the various layers (speciﬁed in the legends). The dotted vertical lines indicate baseline values of
the parameters. Arrows indicate the value of concentration in baseline conditions.
into account by appropriate interface boundary conditions and/or a ﬁctitious advective
ﬁeld for RPE active pumping. Drug concentration levels in the retina have been modeled
distinguishing the tissue phase from the blood phase.
In [], the partial failure in reproducing with the mathematical model the experimen-
tal results is ascribed to the discrepancy of the values of the parameters estimated from
basic physical considerations vs values of the parameters obtained by ﬁtting the model to
experimental data. This fact suggested to explore ranges of parameter values to identify
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Figure 7 Drug time-to-peak in the choroid (left column) and retina (right column) as a function of
diffusion coefﬁcient (top row), clearance rate (middle row) andmembrane permeability (bottom row)
in the various layers (speciﬁed in the legends). The dotted vertical lines indicate baseline values of the
parameters. Arrows indicate the value of time-to-peak in baseline conditions.
characteristic model sensitivities. The authors found a relatively low sensitivity of peak
concentration and time-to-peak in the retina to the diﬀusion and clearance coeﬃcients
and a higher sensitivity to drug resistance (inverse of the drug permeability) of the epis-
cleral layers with respect to peak concentration and to RPE resistance. However, while it
is clearly recognized that a major fraction of the drug is lost from episcleral lymphatics
and blood vessels [], one can think to eliminate the exceedingly large inﬂuence of such a
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Figure 8 Drug peak concentration and time-to-peak as a function of time with active or inactive (‘-’)
selected components of the convective ﬁeld in baseline conditions.
Figure 9 Sensitivity study of the drug peak concentration and time-to-peak values in tissue and
blood phases of the retina with respect to the different components of the convective ﬁeld (ﬁltration
velocity, top row and active pumping, bottom row). The choroid (data not reported) results to be very
weakly sensitive to variations of the convective ﬁeld values.
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mechanism and just focus on the area from sclera to vitreous. Varying the parameters in
the same range as in [] yields in this work sensitivities which reﬂect comparable, if not
more important, roles of diﬀusion and clearance rates.
As for the convective ﬁeld, it is apparent that the ﬁltration velocity is too low to induce
signiﬁcant changes (see Figure ). Diﬀerent is the case of the active pumping velocity. Ac-
cordingly to what found in [] and [] (notice that in these references, the authors repre-
sent this same mechanism in a diﬀerent way), active pumping plays a very relevant role, if
one looks speciﬁcally at the retina and possibly at the vitreous. It is interesting to observe
the shape of the curves with respect to drug permeability. Both for peak concentration and
time-to-peak, the curves results relatively ﬂat even varying the parameter of  or  decades
in log scale. This is probably due to permeability not being a limiting phenomenon in these
regions. The iBRB drug permeability does not seem to have amajor role except for a region
of diameter spanning about  decade at the left and at the right of the baseline value, where
the slope of the curve is comparable to the other ones. The mild inﬂuence of iBRB might
due to having neglected the complexity of active/carried-mediated transport mechanisms
across these interfaces andhaving considered a single partition coeﬃcient across the vessel
walls in both (inward and outward) directions. Representing active pumping as a ﬁctitious
velocity and not as a membrane eﬀect, hinders the role of RPE (see [] for this choice).
An important result of the present analysis is the way in which a % increase of the
drug peak concentration in choroid and retina can be obtained from the baseline val-
ues, for example to meet a therapeutic threshold. Assuming continuous dependence of
the solution on data - a property which can be inferred via a mathematical analysis not
much diﬀerent to the one performed in the Appendix - it is found that such an increase
can be obtained acting on (i) scleral biophysical parameters and then on choroidal and
retinal ones; (ii) active pumping. As for (i), in the neighborhood of baseline conditions,
diﬀusion and clearance appear to play a comparable role, because comparable variations
in the scleral diﬀusion (increase) or scleral clearance (decrease) are required to increase
drug peak concentration (notice the slope of the curves in Figure ). The sclera is per-
meable to hydrophilic compounds, even macromolecules, but the permeability in the
RPE/choroid/Bruch’s membrane is - orders of magnitude lower than in the sclera [].
Moreover, the trend line of decreasing choroid-Bruch’s membrane permeability with in-
creasing solute lipophilicity and/or molecular radius appears to be steeper than the sclera.
However, the simulations suggest that the slope of the sensitivity curves is always higher
for the scleral parameters that for the choroidal ones. Moreover, sensitivity in a certain
layer is higher to properties of layers located at its left side than at its right side. This is a
natural consequence of the positioning of the source. In particular, referring to the theo-
retical analysis carried out for the retinal domain, this implies that the drug concentration
in the choroid is always responsible for the upper bound. As for (ii), pro-drugs have been
envisaged as carriers able to favorably enhance drug delivery. This a very advanced issue
in pharmacokinetics, we refer to [] for a general review.
The present model does not allow to provide data regarding the D spatial distribution
of the drug on the eye globe. While this aspect is very important and has been recently
considered in a few mathematical models [, , ], it remains very diﬃcult to compare
results from such models with experiments. Unknown boundary conditions in the D
models, on the one hand, and tissue homogenization after explant with loss of spatial de-
pendence, on the other, are just examples of such problems.
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Appendix: Bounds for drug concentration in the retina
The retina is an important target for therapies to contrast several disorders, including di-
abetic retinopathy, age-related macular degeneration, and retinitis pigmentosa []. The
retina has a unique position with regard to pharmacokinetics, being separated from cir-
culating blood by the BRBs, makes it a very diﬃcult target. In this section, we theoretically
establish the bounds for drug concentration predicted by the model in the retinal domain
R, assuming for simplicity no convective ﬁeld. To do this, we assume the drug concen-
tration at the interface with the adjacent choroid (C¯C = C¯C(t)) and vitreous (C¯V = C¯V (t))
to be known functions, so that the boundary conditions for the domain R become:
–DRt
∂CRt
∂x · nRt =LCR(PCRCRt – C¯C) on CR, ()
–DRt
∂CRt
∂x · nRt =LRV (PRVCRt – C¯V ) on RV . ()
In the sequel, L(R) will denote the space of measurable functions whose square is
Lebesgue integrable in R. The space L(R) is equipped with the norm ‖ · ‖L(R).
We denote with (·, ·) its scalar product both for scalar and vector functions. We intro-
duce the Sobolev space H(R), which denotes functions that belong to L(R) along
with their ﬁrst order distributional derivative in space. For v ∈ H(R), we denote by
∂xv such a derivative. The space H(R) is equipped with the norm ‖ · ‖H(R). We also
need to introduce the spaces L(,T ;V ) = {v : (,T)→ V |v(t) is measurable,‖v‖L(,T ;V ) :=∫ T
 ‖v(t)‖V dt < +∞}, with V = H(R) or L(R), and L∞(,T ;L(R)) = {v : (,T) →
L(R)|v(t) is measurable,‖v(t)‖L(R) is essentially bounded in (,T)}, endowed with the
norm ‖v‖L∞(,T ;L(R)) := inf{M >  : ‖v(t)‖L(R) ≤M a.e. in (,T)}. For v ∈ L(,T ;V ), we
denote by ∂tv its derivative with respect to time, such that ∂tv ∈ L(,T ;V ′(R)), V ′ being
the dual space of V , and ∀u ∈ L(,T ;V ), 〈∂tv(t),u(t)〉 =
∫
R
∂tvudx represents a duality
pairing. We here assume for simplicity that DR, kRt , kRb, LCR, LRV are positive constants
and that β ∈ L∞(R) and CRb,,CRt, ∈ L(R). We let φ ∈ C(¯R) with φm = minx∈R φ(x)
and φM = maxx∈R φ(x).
The weak counterpart of the multiphase system () reads:
- in the tissue phase, ﬁnd CRt = CRt(t,x) ∈ L(,T ;H(R)) with
∂tCRt ∈ L(,T ;H–(R)), such that:
〈
( – φ)∂tCRt , v
〉
+DR
(
( – φ)∂xCRt , ∂xv
)
+
(
kR( – φ)CRt , v
)
+
(
β(CRt –CRb), v
)
+LCR
(
( – φ)(CRt –PCRC¯C), v
)|CR
+LRV
(
( – φ)(PRVCRt – C¯V )v
)|RV =  ∀v ∈H(R); ()
- in the blood phase, ﬁnd CRb = CRb(t,x) ∈ L(,T ;L(R)) with
∂tCRb ∈ L(,T ;L(R)), such that:
〈φ∂tCRb,w〉 + (kRbφCRb,w) +
(
β(CRb –CRt),w
)
= (SRb,w) ∀w ∈ L(R). ()
We prove that the drug concentration in the multiphase model is non-negative and
bounded above by a maximal value CN depending on the initial conditions, boundary
data and external sources. In doing this, we neglect the convective ﬁeld.
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Theorem  Let CN := max{maxt∈(,T){PCRC¯C , C¯VPRV ,
λ(t)
kRb },maxx∈R{CRb,,CRt,}}. Then, the
solution CR = CR(t,x) = [CRt(t,x),CRb(t,x)] of problem ()-() satisﬁes  ≤ CR(t,x) ≤ CN
a.e. in R × (,T).
Proof of Theorem  We face the multiphase problem in the retina in a decoupled manner
by introducing the following Gauss-Seidel iterative procedure:
Given  ≤ CRb ≤ CN a.e. in R × (,T), ∀k = , , . . . , ﬁnd CkR = [CkRt ,CkRb] ∈ L(,T ;
H(R))× L(,T ;L(R)) such that it yields:
- in the tissue phase
〈
( – φ)∂tCkRt , v
〉
+DR
(
( – φ)∂xCkRt , ∂xv
)
+
(
kR( – φ)CkRt , v
)
+
(
β
(
CkRt –Ck–Rb
)
, v
)
+LCR
(
( – φ)
(
CkRt –PCRC¯C
)
, v
)|CR
+LRV
(
( – φ)
(PRVCkRt – C¯V )v)|RV =  ∀v ∈H(R); ()
- in the blood phase
〈
φ∂tCkRb,w
〉
+
(
kRbφCkRb,w
)
+
(
β
(
CkRb –CkRt
)
,w
)
= (SRb,w) ∀w ∈ L(R). ()
We verify by a recursive argument that the sequence CkR satisﬁes  ≤ CkR ≤ CN . The key
point is given by the following lemma, for k = , , . . . .
Lemma  Given  ≤ Ck–Rb ≤ CN in R × (,T), then  ≤ CkRt ≤ CN in R × (,T). Con-
versely, given ≤ CkRt ≤ CN in R × (,T), then ≤ CkRb ≤ CN in R × (,T).
Proof of Lemma  Let 	 be a constant. For any u ∈ V , we introduce the non-negative func-
tions [u – 	]+ = max{u – 	, }, [u – 	]– = max{	 – u, }, such that [u – 	]+, [u – 	]– ∈ V . We
refer to [] for the properties of such functions.
We start proving that CkR ≥  under the hypothesis that Ck–Rb ≥ . We set 	 =  and
choose v = –[CRt]– as a test function in (), yielding

 ( – φM)
d
dt
∥∥[CkRt]–∥∥L(R) +DR( – φM)
∥∥∂x[CkRt]–∥∥L(R)
+
(
kR( – φM) + β(φm)
)∥∥[CkRt]–∥∥L(R)
+LRVPRV
(
( – φ)
([
CkRt
]–))
|RV
+LCR
(
( – φ)
([
CkRt
]–))
|CR
≤ –β(φm)
∫
R
Ck–Rb
[
CkRt
]– dx –LCRPCRC¯C(( – φ)[CkRt]–)|CR
–LRV C¯V
(
( – φ)
[
CkRt
]–)
|RV
. ()
The right-hand of side of () is non-positive for a.e. t ∈ (,T). Integrating in time over
(, t) and using the fact that [CkRt,]– = , we obtain
∥∥[CkRt(t)]–∥∥L(R) + DR
∫ t

∥∥∂x[CkRt]–∥∥L(R) + 
(
kR +
β(φm)
 – φM
)∫ t

∥∥[CkRt]–∥∥L(R)
+ LRVPRV
∫ t

([
CkRt
]–)
|RV
+ LCR
∫ t

([
CkRt
]–)
|CR
≤ . ()
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We evaluate the integrals at the left-hand side of () for t = T and integrate once again,
this time on [,T], obtaining:
min
{
 + T
(
kR +
β(φm)
 – φM
)
, DRT
}∥∥[CkRt]–∥∥L(,T ;H(R))
+ TLRVPRV
∫ T

([
CkRt
]–
|RV
) + TLCR
∫ T

([
CkRt
]–
|CR
) ≤ . ()
From ()we deduce that [CkRt(t)]– =  and thusCkRt ≥  a.e. inR×(,T). Now,we choose
v = –[CRb]– as a test function in (), yielding

φm
d
dt
∥∥[CkRb]–∥∥L(R) +
(
β(φm) + φmkRb
)∥∥[CkRb]–∥∥L(R)
≤ –β(φm)
∫
R
(
CkRt
)[
CkRb
]– dx –
∫
R
SRb(t,φm)
[
CkRb
]– dx. ()
Thanks to the previous result and to the hypotheses on the external source, the right-hand
of side of () is non-positive for a.e. t ∈ (,T). Integrating in time over (, t) and using the
fact that [CkRt,]– = , we obtain:
∥∥[CkRb(t)]–∥∥L(R) + 
(
β(φm)
φm
+ kRb
)∫ t

∥∥[CkRb]–∥∥L(R)
≤ –β(φm)
φm
∫ t

∫
R
(
CkRt
)[
CkRb
]– dx – 
∫ t

∫
R
SRb(t,φm)
φm
[
CkRb
]– dx. ()
We evaluate the integrals at the left-hand side for t = T and integrate once again, this time
on [,T], obtaining:
(
 + T
(
β(φm)
φm
+ kRb
))∥∥[CkRb]–∥∥L(,T ;L(R)) ≤ . ()
From () we deduce that [CkRb(t)]– =  and thus CkRb ≥  a.e. in R × (,T).
Now we prove that CkR ≤ CN under the hypothesis Ck–Rb ≤ CN . We set 	 = CN and we
choose v = [CkRt –CN ]+ as a test function in (), yielding
min
{
 + T
(
kR +
β(φm)
 – φM
)
, DRT
}∥∥[CkRt –CN]+∥∥L(,T ;H(R))
+CNkRT
∫ T

∫
R
[
CkRt –CN
]+ dxdt
+ β(φm) – φM
T
∫ T

∫
R
[
CkRt –CN
]+(CN –Ck–Rb )dxdt
+LRVPRVT
∫ T

([
CkRt –CN
]+)
|RV
dt +LCRT
∫ T

([
CkRt –CN
]+)
|CR
dt
+LRV (PRVCN – C¯V )T
∫ T

[
CkRt –CN
]+
|RV
dt
+LCRT
∫ T

(CN –PCRC¯C)
[
CkRt –CN
]+
|CR
dt ≤ . ()
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Proceeding in a similar way as above, we deduce that ‖[CkRt –CN ]+‖L(,T ;H(R)) = , which
directly implies that CkRt ≤ CN a.e. in R × (,T). Now, we choose v = [CkRb –CN ]+ as a test
function in (), yielding
φm


d
dt
∥∥[CkRb –CN]+∥∥L(R) +
(
φmkRb + β(φm)
)∥∥[CkRb –CN]+∥∥L(R)
≤ –β(φm)
∫
R
(
CN –CkRt
)[
CkRb –CN
]+ dx
–
∫
R
(
φ
(
kRbCN – λ(t)
))[
CkRb –CN
]+ dx. ()
Upon observing that all the terms at the right and side are non-positive, we integrate in
time over (,T) using the fact that [CkRb, –CN ]+ =  and we integrate once again on [,T],
obtaining
(
φm + T
(
β(φm) + φmkRb
))∥∥[CkRb –CN]+∥∥L(,T ;L(R)) ≤ .
We deduce that ‖[CkRb – CN ]+‖L(,T ;L(R)) = , that directly implies that CkRb ≤ CN a.e. in
R × (,T). 
To conclude the theorem, we prove the following lemma.
Lemma  The sequence CkR converges to the solution of system ()-(), precisely
lim
k→∞
∥∥CRt –CkRt∥∥L(,T ;H(R)) = ,
lim
k→∞
∥∥CRb –CkRb∥∥L(,T ;L(R)) = ,
lim
k→∞
∥∥CR –CkR∥∥L∞(,T ;[L(R)]) = .
Proof of Lemma  We introduce the splitting errors ekRt := CRt – CkRt , ekRb := CRb – CkRb. We
observe that ekRt ∈ H(R) and ekRb ∈ L(R). We subtract the corresponding equations of
()-() from equations ()-(), and we choose as tests functions ekRt and ekRb in the ﬁrst
and second system, respectively. Then we integrate each equation over (,T) and sum up
the two inequalities, term by term. Noticing that ekRt = ekRb =  at time t =  for all k and
considering the summation over k from  to a given indexM, we have at time T ,
M∑
k=
(
( – φM)
∥∥ekRt∥∥L(R) + φm
∥∥ekRb∥∥L(R) + ( – φM)DR
∫ T

∥∥∂xekRt∥∥L(R) dt
+ ( – φM)kRt
∫ T

∥∥ekRt∥∥L(R) dt + φmkRb
∫ T

∥∥ekRb∥∥L(R) dt
+ ( – φM)LRVPRV
∫ T

(
ekRt
)
|RV
dt + ( – φM)LCR
∫ T

(
ekRt
)
|CR
dt
)
+ β(φm)
∫ T

(∥∥eMRb∥∥)L(R) dt
≤ β(φm)
∫ T

(∥∥eRb∥∥)L(R) dt. ()
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Taking the limit forM → +∞ and noting that the sum is bounded above, we have that
lim
k→∞
∥∥ekj ∥∥L(R) = , limk→∞
∥∥ekj ∥∥L((,T);V ) = , j = Rb,Rt. 
From the boundedness of CkR in R × (,T) for all k ≥ , it is then straightforward to
prove that ≤ CR ≤ CN a.e. in R × (,T) []. 
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